凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花生物:2014年第一季度报告

公告日期 2014-04-26
股票简称:梅花生物 股票代码:600873
梅花生物科技集团股份有限公司
           600873



    2014 年第一季度报告
600873                            梅花生物科技集团股份有限公司 2014 年第一季度报告




                              目 录
一、重要提示........................................................ 2

二、公司主要财务数据和股东变化...................................... 3

三、重要事项........................................................ 5

四、附录............................................................ 8




                                  1
600873                                    梅花生物科技集团股份有限公司 2014 年第一季度报告




一、重要提示

1.1   公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、

完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。

1.2   如有董事未出席董事会审议季度报告,应当单独列示该董事姓名及未出席原因。

         未出席董事姓名              未出席董事职务               未出席原因的说明

            刘宏鹏                        董事                        因公出差


1.3
公司负责人姓名                                 孟庆山
主管会计工作负责人姓名                         李勇刚
会计机构负责人(会计主管人员)姓名             陶忠

公司负责人孟庆山、主管会计工作负责人李勇刚及会计机构负责人(会计主管人员)陶忠保

证季度报告中财务报表的真实、准确、完整。


1.4   公司第一季度报告中的财务报表未经审计。




                                           2
 600873                                          梅花生物科技集团股份有限公司 2014 年第一季度报告




二、公司主要财务数据和股东变化
2.1   主要财务数据
                                                                             单位:元 币种:人民币
                                                                             本报告期末比上年度末
                           本报告期末                     上年度末
                                                                                   增减(%)
总资产                    19,698,447,188.94             18,713,590,263.14                    5.26
归属于上市公司股东的
                           8,102,214,659.77              8,027,109,018.71                     0.94
净资产
                                                     上年初至上年报告期
                         年初至报告期末
                                                              末              比上年同期增减(%)
                           (1-3 月)
                                                         (1-3 月)
经营活动产生的现金流
                               -336,705,732.67            -306,710,683.76                  不适用
量净额
                                                     上年初至上年报告期
                         年初至报告期末                                       比上年同期增减(%)
                                                             末
营业收入                   2,099,058,041.30              1,866,927,387.17                    12.43
归属于上市公司股东的
                                75,105,641.06              145,588,542.14                   -48.41
净利润
归属于上市公司股东的
扣除非经常性损益的净            36,275,301.83              111,547,307.34                   -67.48
利润
加权平均净资产收益率
                                          0.93                       2.62       减少 1.69 个百分点
(%)
基本每股收益(元/股)                     0.02                       0.05                      -60
稀释每股收益(元/股)                     0.02                       0.05                      -60


扣除非经常性损益项目和金额:
                                                                            单位:元 币种:人民币

                        项目                                         本期金额(1-3 月)

非流动资产处置损益                                                                      72,499.33
计入当期损益的政府补助,但与公司正常经营业务密切相
关,符合国家政策规定、按照一定标准定额或定量持续享                                  42,680,100.72
受的政府补助除外
除同公司正常经营业务相关的有效套期保值业务外,持有
交易性金融资产、交易性金融负债产生的公允价值变动损
                                                                                     1,467,425.72
益,以及处置交易性金融资产、交易性金融负债和可供出
售金融资产取得的投资收益
除上述各项之外的其他营业外收入和支出                                                   776,084.40
所得税影响额                                                                        -6,165,770.94
                        合计                                                        38,830,339.23


2.2   截至报告期末的股东总数、前十名股东、前十名无限售条件股东的持股情况表

                                                                                       单位:股




                                                 3
600873                                    梅花生物科技集团股份有限公司 2014 年第一季度报告




股东总数(户)                                                                      61,849
前十名股东持股情况
                                                    持有有限
                  股东性    持股比
    股东名称                           持股总数     售条件股       质押或冻结的股份数量
                    质      例(%)
                                                      份数量
                  境内自
孟庆山                        27.48   854,103,033              0   质押        705,070,000
                  然人
                  境内自
胡继军                        11.88   369,394,122              0   质押        369,390,000
                  然人
香港鼎晖生物科    境外法
                                8.1   251,625,120              0   无
技有限公司        人
新天域生化科技    境外法
                                5.7   177,106,616              0   无
投资有限公司      人
建信基金公司-
慧智投资 8 号结
                  其他         3.59   111,640,000              0   无
构化集合资金信
托计划
杨维永            其他        2.54    78,810,526               0   质押          74,900,000
                  境内自
王爱军                        2.29    71,316,274               0   质押          71,316,274
                  然人
南京瑞森投资管 境 内 非
理合伙企业(有 国 有 法         2.1   65,170,000               0   无
限合伙)          人
昆明盈鑫叁壹投 境 内 非
资中心(有限合 国 有 法       2.05    63,800,000               0   无
伙)              人
                  境内自
李宝骏                        1.87    58,020,019               0   质押          56,690,000
                  然人
前十名无限售条件流通股股东持股情况
                          期末持有无限售条件流
    股东名称(全称)                                           股份种类及数量
                               通股的数量
                                                    人民币普
孟庆山                                854,103,033                         854,103,033
                                                    通股
                                                    人民币普
胡继军                                369,394,122                         369,394,122
                                                    通股
香港鼎晖生物科技有限公                              人民币普
                                      251,625,120                         251,625,120
司                                                  通股
新天域生化科技投资有限                              人民币普
                                      177,106,616                         177,106,616
公司                                                通股
建信基金公司-慧智投资 8
                                                    人民币普
号结构化集合资金信托计                111,640,000                         111,640,000
                                                    通股

                                                  人民币普
杨维永                                 78,810,526                  78,810,526
                                                  通股
                                                  人民币普
王爱军                                 71,316,274                  71,316,274
                                                  通股
南京瑞森投资管理合伙企                            人民币普
                                       65,170,000                  65,170,000
业(有限合伙)                                    通股
昆明盈鑫叁壹投资中心(有                          人民币普
                                       63,800,000                  63,800,000
限合伙)                                          通股
                                                  人民币普
李宝骏                                 58,020,019                  58,020,019
                                                  通股
 上述股东关联关系或一致    上述股东中,孟庆山、杨维永和王爱军为一致行动人,其他股
       行动的说明          东未知其一致行动关系。



                                          4
  600873                                     梅花生物科技集团股份有限公司 2014 年第一季度报告



  其他说明:2013 年 12 月 30 日,孟庆山、杨维永、王爱军等五人,共同出具追加限售期的承诺函:
  其持有的公司股份自 2014 年 1 月 2 日上市流通之日起追加限售锁定期 24 个月,即自 2014 年 1

  月 2 日起 24 个月不上市交易或转让,限售期满后按照中国证监会或上海证券交易所的有关规定
  执行。

  三、重要事项
  3.1     公司主要会计报表项目、财务指标重大变动的情况及原因

  √适用 □不适用

  资产负债表:
                                                                   单位:万元 币种:人民币
                                                       增减幅
  项目        本报告期末     上年度期末   增减额                            差异说明
                                                         度%
                                                                 本期销售收入增加以及味精客
应收账款       33,376.59      19,920.42   13,456.17      67.55
                                                                 户授信增加所致。
预付账款       53,011.56      33,895.91   19,115.65      56.40   本期预付玉米款增加
                                                                 本期子公司新疆梅花氨基酸有
在建工程      109,537.86     182,890.47   -73,352.61    -40.11   限责任公司部分项目转固,减
                                                                 少在建工程

应付票据          -           13,276.00   -13,276.00      -100   本期票据到期支付

                                                                 本期应缴增值税及企业所得税
应交税费        4,611.36       2,880.17    1,731.19      60.11
                                                                 增加所致
其他流动
              199,790.02      99,720.02   100,070.00    100.35   本期发行 10 亿短期融资券
负债

  利润表:
                                                                   单位:万元 币种:人民币
                                                       增减幅
   项目         本报告期      上年同期     增减额                           差异说明
                                                         度%
                                                                  本期子公司新疆梅花氨基酸
                                                                  有限责任公司部分项目转固,
财务费用         10,340.03     5,099.64     5,240.39    102.76
                                                                  利息支出由资本化转为费用
                                                                  化支出

投资收益               172        26.44       145.56    550.53    本期理财收益增加
营业外支
                      3.35        51.12       -47.77    -93.45    本期其他支出减少

                                                                  本期味精市场、氨基酸市场面
                                                                  临行业产能过剩,市场竞争加
                                                                  剧的影响,公司主要产品味
净利润            7,510.56    14,558.85    -7,048.29    -48.41
                                                                  精、赖氨酸、苏氨酸等销售价
                                                                  格下滑所致毛利减少,以及本
                                                                  期财务费用增加所致。

  现金流量表:
                                                                   单位:万元 币种:人民币


                                              5
  600873                                     梅花生物科技集团股份有限公司 2014 年第一季度报告



       项目        本报告期     上年同期      增减额      增减幅度%            差异说明
                                                                       本期子公司新疆梅花氨基
投资活动产生的
                  -40,890.35   -72,104.32     31,213.97        43.29   酸有限责任公司在建投入
现金流量净额
                                                                       减少

筹资活动产生的
                   64,580.40   348,410.44   -283,830.04      -81.46    本期吸收投资款项减少
现金流量净额


  3.2    重要事项进展情况及其影响和解决方案的分析说明

  √适用 □不适用

        1.2014 年 4 月 23 日,公司召开 2013 年度股东大会,会上审议通过了 2013 年度利润分

  配方案:公司以现有总股本 3,108,226,603 股为基数,向全体股东每 10 股分配现金红利 1.00

  元(含税),预计分配利润 310,822,660.30 元。公司将择机发布利润分配实施公告,安排现

  金红利发放事宜。

        2.2013 年 4 月 19 日,公司在内蒙古自治区阿荣旗工商行政管理局注册成立了全资子公

  司梅花集团(呼伦贝尔)氨基酸有限公司(下称"呼伦贝尔公司"),具体承担河北基地整体

  异地搬迁项目的实施与建设。鉴于公司已将该项目选址由呼伦贝尔市阿荣旗变更为新疆五家

  渠工业园区新疆梅花氨基酸有限责任公司院内,为优化资源配置,降低管理成本,2014 年 4

  月 25 日,经第七届董事会第五次会议审议通过,公司决定注销呼伦贝尔公司,并授权总经

  理王爱军办理该公司注销涉及到的相关事宜。

  3.3    公司及持股 5%以上的股东承诺事项履行情况

  √适用 □不适用
                                                                                    是否   是否
                                                                         承诺时
承诺     承诺                                                                       有履   及时
                 承诺方                     承诺内容                     间及期
背景     类型                                                                       行期   严格
                                                                           限
                                                                                    限     履行
                            在重组完成后,孟庆山先生及一致行动人将尽
                            量避免与上市公司的关联交易,若有不可避免
                            的关联交易,孟庆山先生及一致行动人与上市    2010 年 7
         解决    孟庆山及
                            公司将依法签订协议,履行合法程序,并将按    月 19 日
与重     关联    其一致行                                                           否      是
                            照有关法律、法规、《公司章程》等有关规定     出具承
大资     交易      动人
                            履行信息披露义务和办理有关报批事宜,保证        诺
产重                        不通过关联交易损害上市公司及其他股东的
组有                        合法权益。
关的
承诺                        在本次交易完成后继续保持上市公司的独立      2010 年 7
                 孟庆山及
                            性,在资产、人员、财务、机构、业务上遵循    月 19 日
         其他    其一致行                                                           否      是
                            五分开原则,遵守中国证监会有关规定,规范     出具承
                   动人
                            运作上市公司。                                 诺




                                              6
  600873                                       梅花生物科技集团股份有限公司 2014 年第一季度报告



                            在孟庆山先生及一致行动人作为上市公司控
                            股股东或实际控制人之期限内,将采取有效措       2010 年 7
        解决   孟庆山及
                            施,并促使孟庆山先生或孟庆山先生及一致行       月 19 日
        同业   其一致行                                                                否     是
                            动人下属控股子公司采取有效措施,不会从事        出具承
        竞争     动人
                            或参与任何可能对上市公司或其控股子公司            诺
                            目前主要从事的业务构成竞争的业务。

               股东孟庆     上述五人持有的公司股份自 2014 年 1 月 2 日     24 个月,
               山、杨维     上市流通之日起追加限售锁定期 24 个月,即       2014 年 1
其他
        其他   永、王爱     自 2014 年 1 月 2 日起 24 个月不上市交易或转    月2日      是     是
承诺
               军、何君、   让,限售期满后按照中国证监会或上海证券交       -2016 年
                 杨维英     易所的有关规定执行。                           1月2日


  3.4   预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变

  动的警示及原因说明

  □适用 √不适用




                                                              梅花生物科技集团股份有限公司

                                                                            法定代表人:孟庆山



                                                                            ________________

                                                                             2014 年 4 月 25 日




                                                7
600873                                   梅花生物科技集团股份有限公司 2014 年第一季度报告




四、附录
                                  合并资产负债表
                                 2014 年 3 月 31 日
编制单位:梅花生物科技集团股份有限公司
                                                                   单位:元 币种:人民币
项目                                          期末余额                       年初余额
流动资产:
    货币资金                            1,696,582,387.30                1,216,617,968.54
    结算备付金
    拆出资金
    交易性金融资产                       128,500,000.00
    应收票据                             149,395,103.79                   157,885,031.98
    应收账款                             333,765,873.59                   199,204,239.81
    预付款项                             530,115,559.82                   338,959,094.26
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                           473,901,799.10                   410,948,756.66
    买入返售金融资产
    存货                                1,824,914,256.34                1,637,414,459.98
    一年内到期的非流动
资产
    其他流动资产                          785,415,942.28                  835,067,662.75
      流动资产合计                      5,922,590,922.22                4,796,097,213.98
非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                         121,851,336.02                   121,598,769.04
    投资性房地产
    固定资产                           11,296,220,737.34               10,636,584,947.54
    在建工程                            1,095,378,602.68                1,828,904,737.50
    工程物资                               33,442,951.40                   31,258,164.87
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                             711,848,088.99                   716,600,248.92
    开发支出
    商誉                                   11,788,911.79                   11,788,911.79
    长期待摊费用
    递延所得税资产                          5,325,638.50                    5,325,638.51
    其他非流动资产                        500,000,000.00                  565,431,630.99
      非流动资产合计                   13,775,856,266.72               13,917,493,049.16
         资产总计                      19,698,447,188.94               18,713,590,263.14
600873                                  梅花生物科技集团股份有限公司 2014 年第一季度报告


流动负债:
    短期借款                           4,269,960,420.60                4,213,045,728.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                                             132,760,000.00
    应付账款                            873,483,034.05                   990,782,105.29
    预收款项                            521,295,124.01                   676,368,865.16
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                         29,520,946.01                    34,063,713.31
    应交税费                             46,113,553.43                    28,801,688.79
    应付利息                            104,553,791.71                    87,926,721.10
    应付股利
    其他应付款                          506,564,535.29                   567,598,726.11
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动
                                       1,000,000,000.00                1,000,000,000.00
负债
    其他流动负债                       1,997,900,181.43                  997,200,241.92
      流动负债合计                     9,349,391,586.53                8,728,547,789.68

非流动负债:

    长期借款                           1,288,533,490.00                1,000,000,000.00
    应付债券                             894,539,893.55                  893,816,933.66
    长期应付款
    专项应付款
    预计负债                                 1,100,000.00                  1,100,000.00
    递延所得税负债
    其他非流动负债                        62,667,559.09                   63,016,521.09
      非流动负债合计                   2,246,840,942.64                1,957,933,454.75
        负债合计                      11,596,232,529.17               10,686,481,244.43
所有者权益(或股东权益):
    实收资本(或股本)                 3,108,226,603.00                3,108,226,603.00
    资本公积                           2,240,485,918.58                2,240,485,918.58
    减:库存股
    专项储备
    盈余公积                            178,950,228.74                   178,950,228.74
    一般风险准备
    未分配利润                         2,574,551,909.45                2,499,446,268.39
    外币报表折算差额
归属于母公司所有者权益
                                       8,102,214,659.77                8,027,109,018.71
合计
    少数股东权益
        所有者权益合计                 8,102,214,659.77                8,027,109,018.71
负债和所有者权益总计                  19,698,447,188.94               18,713,590,263.14
法定代表人:孟庆山       主管会计工作负责人:李勇刚         会计机构负责人:陶忠

                                         9
600873                                   梅花生物科技集团股份有限公司 2014 年第一季度报告


                               母公司资产负债表
                                 2014 年 3 月 31 日
编制单位:梅花生物科技集团股份有限公司
                                                                  单位:元 币种:人民币
              项目                    期末余额                    年初余额
   流动资产:
       货币资金                          369,909,644.13                459,982,912.10
       交易性金融资产
       应收票据                           82,775,152.70                 63,999,952.60
       应收账款                          237,813,244.97                207,667,769.18
       预付款项                          109,212,352.40                193,404,177.05
       应收利息
       应收股利                           300,000,000.00               300,000,000.00
       其他应收款                       6,894,181,920.78             6,346,952,981.20
       存货                               312,493,388.66               206,711,681.78
       一年内到期的非流动资
   产
       其他流动资产                        46,344,536.23                35,285,857.69
         流动资产合计                   8,352,730,239.87             7,814,005,331.60
   非流动资产:
       可供出售金融资产
       持有至到期投资
       长期应收款
       长期股权投资                     5,409,851,336.02             5,409,598,769.05
       投资性房地产
       固定资产                          225,038,460.06                251,973,880.19
       在建工程                            2,037,299.14                  1,794,000.00
       工程物资
       固定资产清理
       生产性生物资产
       油气资产
       无形资产                           42,389,736.56                 43,042,034.93
       开发支出
       商誉
       长期待摊费用
       递延所得税资产                           8,774.68                     8,774.68
       其他非流动资产                     500,000,000.00               500,000,000.00
         非流动资产合计                 6,179,325,606.46             6,206,417,458.85
            资产总计                   14,532,055,846.33            14,020,422,790.45
   流动负债:
       短期借款                         1,639,000,000.00             1,740,000,000.00
       交易性金融负债
       应付票据                                                         10,000,000.00
       应付账款                         1,146,714,846.04               751,357,018.29
       预收款项                           252,237,859.37               390,498,272.59
       应付职工薪酬                                                        211,582.82
       应交税费                           16,496,672.25                 16,672,602.71
       应付利息                           99,588,091.91                 82,573,689.44
       应付股利
       其他应付款                        469,218,177.64              1,117,426,557.69
       一年内到期的非流动负
                                        1,000,000,000.00             1,000,000,000.00
   债
       其他流动负债                     1,997,900,181.43               997,200,241.92


                                         10
600873                                   梅花生物科技集团股份有限公司 2014 年第一季度报告


        流动负债合计                   6,621,155,828.64              6,105,939,965.46
  非流动负债:
      长期借款                         1,000,000,000.00              1,000,000,000.00
      应付债券                           894,539,893.55                893,816,933.66
      长期应付款
      专项应付款
      预计负债
      递延所得税负债
      其他非流动负债
        非流动负债合计                 1,894,539,893.55              1,893,816,933.66
          负债合计                     8,515,695,722.19              7,999,756,899.12
  所有者权益(或股东权益):
      实收资本(或股本)               3,108,226,603.00              3,108,226,603.00
      资本公积                         2,208,701,622.94              2,208,701,622.94
      减:库存股
      专项储备
      盈余公积                           178,950,228.74                178,950,228.74
      一般风险准备
      未分配利润                         520,481,669.46                524,787,436.65
  所有者权益(或股东权益)
                                       6,016,360,124.14              6,020,665,891.33
  合计
        负债和所有者权益
                                      14,532,055,846.33             14,020,422,790.45
  (或股东权益)总计
  法定代表人:孟庆山      主管会计工作负责人:李勇刚        会计机构负责人:陶忠




                                         11
600873                                    梅花生物科技集团股份有限公司 2014 年第一季度报告


                                      合并利润表
                                    2014 年 1—3 月
                                                                     单位:元 币种:人民币
                项目                           本期金额                  上期金额
一、营业总收入                                   2,099,058,041.30        1,866,927,387.17
    其中:营业收入                               2,099,058,041.30        1,866,927,387.17
          利息收入
          已赚保费
          手续费及佣金收入
二、营业总成本                                  2,046,542,628.42         1,724,695,548.57
    其中:营业成本                              1,706,251,901.13         1,458,193,454.18
          利息支出
          手续费及佣金支出
          退保金
          赔付支出净额
          提取保险合同准备金净额
          保单红利支出
          分保费用
          营业税金及附加                            6,838,184.15             7,149,007.64
          销售费用                                143,423,508.43           121,034,292.71
          管理费用                                 86,628,770.10            87,322,441.30
          财务费用                                103,400,264.61            50,996,352.74
          资产减值损失
    加:公允价值变动收益(损失以“-”
号填列)
      投资收益(损失以“-”号填列)                  1,719,992.69             264,440.81
        其中:对联营企业和合营企业
                                                       252,566.97             -261,561.95
的投资收益
      汇兑收益(损失以“-”号填列)
三、营业利润(亏损以“-”号填列)                 54,235,405.57           142,496,279.41
    加:营业外收入                                 43,562,136.10            39,883,472.76
    减:营业外支出                                     33,451.65               511,247.30
      其中:非流动资产处置损失                                                     916.73
四、利润总额(亏损总额以“-”号填
                                                   97,764,090.02           181,868,504.87
列)
    减:所得税费用                                 22,658,448.96            36,279,962.73
五、净利润(净亏损以“-”号填列)                 75,105,641.06           145,588,542.14
    归属于母公司所有者的净利润                     75,105,641.06           145,588,542.14
    少数股东损益
六、每股收益:
    (一)基本每股收益                                       0.02                    0.05
    (二)稀释每股收益                                       0.02                    0.05
七、其他综合收益
八、综合收益总额                                   75,105,641.06           145,588,542.14
归属于母公司所有者的综合收益总额                   75,105,641.06           145,588,542.14
    归属于少数股东的综合收益总额
法定代表人:孟庆山     主管会计工作负责人:李勇刚               会计机构负责人:陶忠

                                          12
600873                                       梅花生物科技集团股份有限公司 2014 年第一季度报告


                                        母公司利润表
                                       2014 年 1—3 月
                                                                           单位:元 币种:人民币
                 项目                         本期金额                      上期金额
 一、营业收入                                     1,304,332,311.86              59,104,610.02
         减:营业成本                             1,204,096,622.22              65,216,550.76
             营业税金及附加                                                        175,223.94
             销售费用                               83,521,249.69                  351,883.20
             管理费用                               22,214,997.66               36,198,527.12
             财务费用                                 2,357,529.74                 840,525.10
             资产减值损失
     加:公允价值变动收益(损失
 以“-”号填列)
         投资收益(损失以“-”
                                                       363,626.69                   -74,038.65
 号填列)
           其中:对联营企业和合
                                                       252,566.97                 -261,561.95
 营企业的投资收益
 二、营业利润(亏损以“-”号填
                                                     -7,494,460.76              -43,752,138.75
 列)
         加:营业外收入                               3,188,693.57                  23,166.59
         减:营业外支出                                                             75,473.60
             其中:非流动资产处置损
                                                                                       473.60
 失
 三、利润总额(亏损总额以“-”
                                                     -4,305,767.19              -43,804,445.76
 号填列)
         减:所得税费用
 四、净利润(净亏损以“-”号填
                                                     -4,305,767.19              -43,804,445.76
 列)
 五、每股收益:
         (一)基本每股收益
         (二)稀释每股收益
 六、其他综合收益
 七、综合收益总额                                    -4,305,767.19              -43,804,445.76
法定代表人:孟庆山            主管会计工作负责人:李勇刚             会计机构负责人:陶忠




                                             13
600873                          梅花生物科技集团股份有限公司 2014 年第一季度报告


                          合并现金流量表
                          2014 年 1—3 月
                                                          单位:元 币种:人民币
           项目            本期金额                       上期金额
 一、经营活动产生的现金
 流量:
     销售商品、提供劳务
                              1,696,557,674.32                1,727,648,290.26
 收到的现金
     客户存款和同业存放
 款项净增加额
     向中央银行借款净增
 加额
     向其他金融机构拆入
 资金净增加额
     收到原保险合同保费
 取得的现金
     收到再保险业务现金
 净额
     保户储金及投资款净
 增加额
     处置交易性金融资产
 净增加额
     收取利息、手续费及
 佣金的现金
     拆入资金净增加额
     回购业务资金净增加
 额
     收到的税费返还
     收到其他与经营活动
                                123,426,025.54                  42,210,834.66
 有关的现金
       经营活动现金流入
                              1,819,983,699.86                1,769,859,124.92
 小计
     购买商品、接受劳务
                              1,719,945,150.89                1,819,124,256.66
 支付的现金
     客户贷款及垫款净增
 加额
     存放中央银行和同业
 款项净增加额
     支付原保险合同赔付
 款项的现金
     支付利息、手续费及
 佣金的现金
     支付保单红利的现金
     支付给职工以及为职
                                145,205,833.74                  77,918,060.10
 工支付的现金
     支付的各项税费              40,822,538.71                  66,519,798.12
     支付其他与经营活动
                                250,715,909.19                 113,007,693.80
 有关的现金
       经营活动现金流出
                              2,156,689,432.53                2,076,569,808.68
 小计
         经营活动产生的
                               -336,705,732.67                 -306,710,683.76
 现金流量净额
 二、投资活动产生的现金
 流量:
     收回投资收到的现金

                                14
600873                                 梅花生物科技集团股份有限公司 2014 年第一季度报告


      取得投资收益收到的
                                         1,467,425.72                     526,002.76
  现金
      处置固定资产、无形
  资产和其他长期资产收回                    60,000.00                        2,000.00
  的现金净额
      处置子公司及其他营
  业单位收到的现金净额
      收到其他与投资活动
  有关的现金
        投资活动现金流入
                                         1,527,425.72                     528,002.76
  小计
      购建固定资产、无形
  资产和其他长期资产支付               136,930,883.21                 721,571,186.30
  的现金
      投资支付的现金                   128,500,000.00
      质押贷款净增加额
      取得子公司及其他营
  业单位支付的现金净额
      支付其他与投资活动
                                       145,000,000.00
  有关的现金
        投资活动现金流出
                                       410,430,883.21                 721,571,186.30
  小计
          投资活动产生的
                                      -408,903,457.49                 -721,043,183.54
  现金流量净额
  三、筹资活动产生的现金
  流量:
      吸收投资收到的现金                                             2,457,778,554.00
      其中:子公司吸收少
  数股东投资收到的现金
      取得借款收到的现金             2,127,553,830.00                3,645,166,626.13
      发行债券收到的现金             1,000,000,000.00
      收到其他与筹资活动
  有关的现金
        筹资活动现金流入
                                     3,127,553,830.00                6,102,945,180.13
  小计
      偿还债务支付的现金             1,790,148,090.00                2,152,224,255.50
      分配股利、利润或偿
                                       111,782,494.97                 182,597,254.83
  付利息支付的现金
      其中:子公司支付给
  少数股东的股利、利润
      支付其他与筹资活动
                                       579,819,280.42                 284,019,305.92
  有关的现金
        筹资活动现金流出
                                     2,481,749,865.39                2,618,840,816.25
  小计
          筹资活动产生的
                                       645,803,964.61                3,484,104,363.88
  现金流量净额
  四、汇率变动对现金及现
                                         4,229,331.89                  -11,166,830.06
  金等价物的影响
  五、现金及现金等价物净
                                       -95,575,893.66                2,445,183,666.52
  增加额
      加:期初现金及现金
                                       557,110,850.67                 580,166,305.18
  等价物余额
  六、期末现金及现金等价
                                       461,534,957.01                3,025,349,971.70
  物余额
法定代表人:孟庆山         主管会计工作负责人:李勇刚      会计机构负责人:陶忠


                                       15
600873                              梅花生物科技集团股份有限公司 2014 年第一季度报告


                             母公司现金流量表
                               2014 年 1—3 月
                                                               单位:元 币种:人民币
           项目                本期金额                      上期金额
一、经营活动产生的现金流
量:
    销售商品、提供劳务收到
                                 969,765,509.35                       63,391,680.28
的现金
    收到的税费返还
    收到其他与经营活动有
                               1,181,603,301.56                      923,535,921.89
关的现金
      经营活动现金流入小
                               2,151,368,810.91                      986,927,602.17

    购买商品、接受劳务支付
                                 682,270,610.30                       56,000,115.44
的现金
    支付给职工以及为职工
                                   9,906,840.39                       10,610,171.28
支付的现金
    支付的各项税费                 3,483,302.16                        4,661,508.43
    支付其他与经营活动有
                               2,229,549,674.23                      936,595,439.79
关的现金
      经营活动现金流出小
                               2,925,210,427.08                    1,007,867,234.94

        经营活动产生的现
                                -773,841,616.17                      -20,939,632.77
金流量净额
二、投资活动产生的现金流
量:
    收回投资收到的现金
    取得投资收益收到的现
                                     111,059.72                          187,523.30

    处置固定资产、无形资产
和其他长期资产收回的现金                                                   2,000.00
净额
    处置子公司及其他营业
单位收到的现金净额
    收到其他与投资活动有
关的现金
      投资活动现金流入小
                                     111,059.72                          189,523.30

    购建固定资产、无形资产
                                    242,679.00                           951,068.51
和其他长期资产支付的现金
    投资支付的现金               -23,552,499.76
    取得子公司及其他营业
单位支付的现金净额
    支付其他与投资活动有
                                 145,000,000.00
关的现金
      投资活动现金流出小
                                 121,690,179.24                          951,068.51

        投资活动产生的现
                                -121,579,119.52                         -761,545.21
金流量净额
三、筹资活动产生的现金流
量:
    吸收投资收到的现金                                             2,457,778,554.00
    取得借款收到的现金           570,000,000.00                    2,100,000,000.00
    发行债券收到的现金         1,000,000,000.00
    收到其他与筹资活动有       1,491,000,000.00                    1,922,109,666.48

                                    16
600873                                   梅花生物科技集团股份有限公司 2014 年第一季度报告


关的现金
      筹资活动现金流入小
                                   3,061,000,000.00                     6,479,888,220.48

    偿还债务支付的现金               671,000,000.00                     1,600,000,000.00
    分配股利、利润或偿付利
                                      76,373,564.55                       124,682,317.06
息支付的现金
    支付其他与筹资活动有
                                   1,509,375,505.66                     2,423,889,990.00
关的现金
      筹资活动现金流出小
                                   2,256,749,070.21                     4,148,572,307.06

        筹资活动产生的现
                                     804,250,929.79                     2,331,315,913.42
金流量净额
四、汇率变动对现金及现金等
                                               0.27                                -0.28
价物的影响
五、现金及现金等价物净增加
                                     -91,169,805.63                     2,309,614,735.16

    加:期初现金及现金等价
                                     159,206,324.10                       176,130,498.65
物余额
六、期末现金及现金等价物余
                                      68,036,518.47                     2,485,745,233.81

法定代表人:孟庆山     主管会计工作负责人:李勇刚           会计机构负责人:陶忠




                                         17
数据加载中...
prevnext
手机查看股票